MCID: MYL005
MIFTS: 67

Myelofibrosis malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Myelofibrosis

Aliases & Descriptions for Myelofibrosis:

Name: Myelofibrosis 38 12 50 29 52 14 69
Primary Myelofibrosis 12 50 25 52 42 69
Agnogenic Myeloid Metaplasia 12 50 25 52
Myeloid Metaplasia 50 25 52 69
Idiopathic Myelofibrosis 50 25 52
Megakaryocytic Myelosclerosis 12 69
Myelofibrosis with Myeloid Metaplasia 25
Chronic Idiopathic Myelofibrosis 25
Bone Marrow Fibrosis 12
Aleukemic Myelosis 12
Myelosclerosis 12

Classifications:



Summaries for Myelofibrosis

NIH Rare Diseases : 50 myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue. when the bone marrow is scarred, it cannot make enough blood cells. this leads to anemia, weakness, fatigue, and often, swelling of the liver and spleen. the condition occurs when blood stem cells develop somatic mutations in the jak2, mpl, calr, and tet2 genes. other genes may also be involved. the condition is generally not inherited. although myelofibrosis can occur at any age, it typically develops after the age of 50. in most cases, myelofibrosis gets progressively worse. treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.    last updated: 6/22/2016

MalaCards based summary : Myelofibrosis, also known as primary myelofibrosis, is related to myeloproliferative neoplasm and hemophagocytic lymphohistiocytosis. An important gene associated with Myelofibrosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Trazodone and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A myeloid neoplasm that is located in the bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue.

Genetics Home Reference : 25 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.

Wikipedia : 71 Myelofibrosis, also known as osteomyelofibrosis, is a relatively rare bone marrow cancer. It is... more...

Related Diseases for Myelofibrosis

Diseases in the Myelofibrosis family:

Familial Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 32.2 JAK2 MPL THPO
2 hemophagocytic lymphohistiocytosis 29.0 FLT3 JAK2 KIT MPL STAT5B THPO
3 acute panmyelosis with myelofibrosis 12.3
4 myelofibrosis with myeloid metaplasia, somatic 12.2
5 familial myelofibrosis 11.9
6 cellular phase chronic idiopathic myelofibrosis 11.8
7 hereditary thrombocytopenia with early-onset myelofibrosis 11.7
8 gray platelet syndrome 11.4
9 essential thrombocythemia 11.2
10 neutropenia, severe congenital, 5, autosomal recessive 10.8
11 bleeding disorder, platelet-type, 17 10.8
12 thrombocytopenia 6 10.8
13 polycythemia 10.4
14 leukemia 10.4
15 adiponectin deficiency 10.3 CALR THPO
16 ectodermal dysplasia, ectrodactyly, and macular dystrophy 10.2 MPL THPO
17 poems syndrome 10.2 EPO TET2 THPO
18 ocular hyperemia 10.2 JAK2 MPL THPO
19 pyloric stenosis, infantile hypertrophic, 4 10.2 EPO GATA1 JAK2
20 thrombocytopenia, congenital amegakaryocytic 10.2 MPL THPO
21 blood coagulation disease 10.2 EPO MPL THPO
22 acute liver failure 10.2 EPO GATA1 JAK2
23 osteogenesis imperfecta, type viii 10.2 CALR JAK2 MPL TET2
24 von hippel anomaly 10.2 EPO JAK2 MPL TET2
25 fiedler's myocarditis 10.2 JAK2 TGFB1 THPO
26 granulomatous hepatitis 10.2 EPO JAK2 MPL THPO
27 demyelinating polyneuropathy 10.2 BMP6 EPO TGFB1
28 leiomyomatosis 10.1 CD177 KIT
29 perichondritis of auricle 10.1 JAK2 MPL THPO
30 stevens-johnson syndrome/toxic epidermal necrolysis 10.1 BMP6 FGF2 TGFB1
31 immunodeficiency 20 10.1 IFNA2 MPL THPO
32 apert syndrome 10.1 BMP6 FGF2 TGFB1
33 splenomegaly 10.1
34 glycerol kinase deficiency, adult form 10.1 BMP6 FGF2 KIT
35 craniofrontonasal dysplasia 10.1 GATA1 THPO
36 bladder diffuse clear cell adenocarcinoma 10.1 FGF2 TGFB1
37 colorectal adenoma 10.1 FLT3 JAK2 TET2
38 acute respiratory distress syndrome 10.1 FLT3 JAK2 KIT
39 spondylocostal dysostosis 2 10.1 EPO IFNA2 JAK2 MPL
40 agammaglobulinemia 8, autosomal dominant 10.1 FLT3 JAK2 KIT
41 myelodysplastic syndrome 10.1
42 familial hyperaldosteronism 10.1 FLT3 JAK2 KIT
43 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 10.0 EPO JAK2 STAT5B THPO
44 drug-induced hepatitis 10.0 EPO GATA1 JAK2 MPL THPO
45 temporomandibular ankylosis 10.0 IFNA2 JAK2 KIT TET2
46 myeloid leukemia 10.0
47 hematopoietic stem cell transplantation 10.0
48 focal epilepsy 10.0 CALR JAK2 MPL STAT5B TET2
49 speech and communication disorders 10.0 BMP6 TGFB1 TIMP1
50 lymphoma 10.0

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to Myelofibrosis

Symptoms & Phenotypes for Myelofibrosis

MGI Mouse Phenotypes related to Myelofibrosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CD177 EPO FGF2 FLT3 GATA1 JAK2
2 cellular MP:0005384 10.22 CALR EPO FGF2 FLT3 GATA1 JAK2
3 homeostasis/metabolism MP:0005376 10.22 CALR EPO FGF2 FKBP5 FLT3 GATA1
4 growth/size/body region MP:0005378 10.2 BMP6 CALR FLT3 GATA1 JAK2 KIT
5 immune system MP:0005387 10.15 TGFB1 THPO TIMP1 CD177 EPO FLT3
6 mortality/aging MP:0010768 10.07 CALR EPO FGF2 FKBP5 FLT3 GATA1
7 liver/biliary system MP:0005370 9.87 GATA1 JAK2 KIT STAT5B TET2 TGFB1
8 neoplasm MP:0002006 9.7 FGF2 FLT3 JAK2 KIT TET2 TGFB1
9 reproductive system MP:0005389 9.56 BMP6 FGF2 FKBP5 JAK2 KIT STAT5B
10 skeleton MP:0005390 9.28 BMP6 EPO FGF2 FLT3 GATA1 JAK2

Drugs & Therapeutics for Myelofibrosis

Drugs for Myelofibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 663)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
2
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
3
Minocycline Approved, Investigational Phase 4,Phase 1 10118-90-8 5281021
4
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2 104632-26-0 59868 119570
7
Aminocaproic Acid Approved, Investigational Phase 4 60-32-2 564
8
Tranexamic Acid Approved Phase 4 1197-18-8 5526
9
Lopinavir Approved Phase 4,Phase 3,Phase 2 192725-17-0 92727
10
Enfuvirtide Approved, Investigational Phase 4,Phase 3 159519-65-0 16130199
11
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
15 Piracetam Approved Phase 4,Phase 3 7491-74-9
16
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
17
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
18
Etanercept Approved, Investigational Phase 4,Phase 3 185243-69-0
19
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
20
Leflunomide Approved, Investigational Phase 4,Phase 3 75706-12-6 3899
21
Sulfasalazine Approved Phase 4,Phase 3 599-79-1 5353980 5359476
22
Armodafinil Approved, Investigational Phase 4,Phase 3 112111-43-0
23
Modafinil Approved, Investigational Phase 4,Phase 3 68693-11-8 4236
24
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-20-8, 91374-21-9 5095 497540
25
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
26
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
27
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
28
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
29
Oxcarbazepine Approved Phase 4 28721-07-5 34312
30
Tiagabine Approved Phase 4 115103-54-3 60648
31
Topiramate Approved Phase 4 97240-79-4 5284627
32
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
33
Capsaicin Approved Phase 4 404-86-4 1548943
34
Ziprasidone Approved Phase 4 146939-27-7 60854
35
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
36
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
37
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
38
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
39
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
40
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
41
Insulin Glargine Approved Phase 4 160337-95-1
42
Zinc Approved Phase 4 7440-66-6 32051 23994
43
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
44
Nevirapine Approved Phase 4 129618-40-2 4463
45
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 1,Phase 2 9004-61-9 53477741 24759
46
Benzocaine Approved Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
47
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
48
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
49
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
50
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216503-57-0

Interventional clinical trials:

(show top 50) (show all 830)
id Name Status NCT ID Phase
1 Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans Unknown status NCT01662297 Phase 4
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4
3 A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS Completed NCT00349531 Phase 4
4 Community Health Worker Reduces Care Utilization Completed NCT00711152 Phase 4
5 Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement Completed NCT01873768 Phase 4
6 Value of Urodynamic Evaluation Completed NCT00803959 Phase 4
7 A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort Completed NCT00268827 Phase 4
8 QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Completed NCT00232908 Phase 4
9 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4
10 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4
11 Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED) Completed NCT00358527 Phase 4
12 Daily Activity After Corticosteroids Injection Among Knee Osteoarthritis Patients Completed NCT02049879 Phase 4
13 Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder Completed NCT01195363 Phase 4
14 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
15 The Effects of Levetiracetam on Alcohol Dependent Subjects Completed NCT00325182 Phase 4
16 Understanding Treatment Response With Naltrexone Among White Alcoholics Completed NCT00817089 Phase 4
17 An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia Completed NCT00524043 Phase 4
18 Late-Onset Treatment Study Extension Protocol Completed NCT00455195 Phase 4
19 Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children Completed NCT00139113 Phase 4
20 P4 (Pregabalin for Peripheral Posttraumatic Pain) Completed NCT00292188 Phase 4
21 Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN) Completed NCT01455428 Phase 4
22 Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel) Completed NCT01313208 Phase 4
23 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4
24 Long-term Study Of Ropinirole In Restless Legs Syndrome Completed NCT00329602 Phase 4
25 A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA) Completed NCT01185288 Phase 4
26 Yoga for the Management of HIV-Metabolic Syndromes Completed NCT00627380 Phase 4
27 Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain Completed NCT00313820 Phase 4
28 Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency Completed NCT00684424 Phase 4
29 Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures Completed NCT00537940 Phase 4
30 Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study Completed NCT01679964 Phase 4
31 A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice Completed NCT00855738 Phase 4
32 A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment Completed NCT01713426 Phase 4
33 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4
34 Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER). Completed NCT00288639 Phase 4
35 Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Completed NCT00711516 Phase 4
36 Switch to Unboosted Atazanavir With Tenofovir Study Completed NCT01351740 Phase 4
37 DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy Completed NCT00116116 Phase 4
38 Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia Completed NCT00088049 Phase 4
39 Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings Completed NCT00177398 Phase 4
40 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4
41 Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment Completed NCT00379405 Phase 4
42 Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients Completed NCT00335686 Phase 4
43 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4
44 HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients Recruiting NCT02273791 Phase 4
45 HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients Recruiting NCT02330757 Phase 4
46 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4
47 Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients Recruiting NCT02086474 Phase 4
48 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP Recruiting NCT03119974 Phase 4
49 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Recruiting NCT02741076 Phase 4
50 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029) Active, not recruiting NCT03028974 Phase 4

Search NIH Clinical Center for Myelofibrosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelofibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: primary myelofibrosis

Genetic Tests for Myelofibrosis

Genetic tests related to Myelofibrosis:

id Genetic test Affiliating Genes
1 Myelofibrosis 29

Anatomical Context for Myelofibrosis

MalaCards organs/tissues related to Myelofibrosis:

39
Bone, Bone Marrow, Myeloid, Spleen, Liver, T Cells, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Myelofibrosis:

18
The Bone Marrow Which Results_in Bone Marrow Being Replaced By Fibrous (Scar) Tissue

Publications for Myelofibrosis

Articles related to Myelofibrosis:

(show top 50) (show all 1015)
id Title Authors Year
1
'Janus kinase-ing' up the treatment of primary myelofibrosis: building better combination strategies. ( 28072602 )
2017
2
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. ( 27983880 )
2017
3
Risk stratification in myelofibrosis: the quest for simplification. ( 28040786 )
2017
4
BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation. ( 28484156 )
2017
5
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. ( 28504024 )
2017
6
F-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Appearance of Extramedullary Hematopoesis in a Case of Primary Myelofibrosis. ( 28533647 )
2017
7
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. ( 28464892 )
2017
8
p.Y317H is a new JAK2 gain-of function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation. ( 28473624 )
2017
9
Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. ( 28098757 )
2017
10
Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. ( 27730343 )
2017
11
Liver function test abnormalities and their clinical relevance in primary myelofibrosis. ( 28430173 )
2017
12
Allogeneic Stem Cell Transplantation in Myelofibrosis. ( 28499938 )
2017
13
Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. ( 28509339 )
2017
14
An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis. ( 28529309 )
2017
15
Molecular profiling as a novel tool to predict response to interferon-I+2 in MPNs: The proof of concept in early myelofibrosis. ( 28518284 )
2017
16
Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis. ( 28436280 )
2017
17
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. ( 27885272 )
2017
18
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. ( 28465517 )
2017
19
A novel homozygous VPS45 p.P468L mutation leading to severe congenital neutropenia with myelofibrosis. ( 28453180 )
2017
20
Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. ( 28481328 )
2017
21
Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis. ( 28478151 )
2017
22
Investigational Janus kinase inhibitors in development for myelofibrosis. ( 28441920 )
2017
23
Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis. ( 28502030 )
2017
24
Transplantation in Myelofibrosis Reaches the Molecular Age. ( 28476489 )
2017
25
The effect of initial molecular profile on response to recombinant interferon-I+ (rIFNI+) treatment in early myelofibrosis. ( 28518222 )
2017
26
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. ( 28512865 )
2017
27
A rare case of myelofibrosis secondary to juvenile idiopathic arthritis. ( 27102067 )
2016
28
Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis. ( 25913509 )
2016
29
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. ( 28008177 )
2016
30
Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone. ( 27562925 )
2016
31
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. ( 28009442 )
2016
32
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. ( 27598824 )
2016
33
JAK2(V617F) allele burden ac350% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. ( 26975727 )
2016
34
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. ( 27114459 )
2016
35
The Degree of Anisocytosis Predicts Survival in Patients with Primary Myelofibrosis. ( 27189016 )
2016
36
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence. ( 27592020 )
2016
37
Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone. ( 27526305 )
2016
38
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis. ( 27538006 )
2016
39
Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan. ( 26214121 )
2016
40
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. ( 27106071 )
2016
41
Primary myelofibrosis and its targeted therapy. ( 27539616 )
2016
42
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. ( 27143923 )
2016
43
Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. ( 27935577 )
2016
44
Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis. ( 27214077 )
2016
45
Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2a88years follow-up. ( 28011890 )
2016
46
Kinase signaling and targeted therapy for primary myelofibrosis. ( 28043820 )
2016
47
Immunohistochemical staining of transcription factor NFE2 for the discrimination of primary myelofibrosis from essential thrombocythemia. ( 27038682 )
2016
48
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. ( 27167495 )
2016
49
Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis. ( 27477402 )
2016
50
Managing patients with myelofibrosis and low platelet counts. ( 27209535 )
2016

Variations for Myelofibrosis

ClinVar genetic disease variations for Myelofibrosis:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MPL NM_005373.2(MPL): c.1543_1544delTGinsAA (p.Trp515Lys) indel Pathogenic rs121913616 GRCh37 Chromosome 1, 43815008: 43815009
2 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh37 Chromosome 1, 43814979: 43814979
3 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913615 GRCh37 Chromosome 1, 43815009: 43815009
4 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
5 SH2B3 NM_005475.2(SH2B3): c.603_607delGCGCT (p.Arg202Glnfs) deletion Pathogenic rs587776885 GRCh37 Chromosome 12, 111856552: 111856556
6 CALR NM_004343.3(CALR): c.1092_1143del52 (p.Leu367Thrfs) deletion Pathogenic GRCh37 Chromosome 19, 13054565: 13054616

Copy number variations for Myelofibrosis from CNVD:

7 (show top 50) (show all 1783)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13799 1 1 5300000 Copy-Neutral LOH GABRD Myelofibrosis
2 13967 1 102000000 107000000 Amplification without LOH AMY2A Myelofibrosis
3 13968 1 102000000 107000000 Deletion without LOH COL11A1 Myelofibrosis
4 13969 1 102000000 107000000 Deletion without LOH PRMT6 Myelofibrosis
5 14306 1 107000000 111600000 Amplification without LOH GSTM1 Myelofibrosis
6 14307 1 107000000 111600000 Amplification without LOH GSTM5 Myelofibrosis
7 14308 1 107000000 111600000 Amplification without LOH KCNC4 Myelofibrosis
8 14310 1 107000000 111600000 Deletion without LOH FAM102B Myelofibrosis
9 14311 1 107000000 111600000 Deletion without LOH NBPF6 Myelofibrosis
10 14313 1 107000000 111600000 Deletion without LOH WDR47 Myelofibrosis
11 14960 1 111600000 115900000 Amplification without LOH KCND3 Myelofibrosis
12 14961 1 111600000 115900000 Amplification without LOH TRIM33 Myelofibrosis
13 14962 1 111600000 115900000 Deletion without LOH CTTNBP2NL Myelofibrosis
14 15472 1 115900000 117600000 Amplification without LOH ATP1A1 Myelofibrosis
15 15473 1 115900000 117600000 Amplification without LOH CASQ2 Myelofibrosis
16 15635 1 117600000 120700000 Deletion without LOH PHGDH Myelofibrosis
17 15636 1 117600000 120700000 Deletion without LOH VTCN1 Myelofibrosis
18 15637 1 117600000 120700000 Deletion without LOH ZNF697 Myelofibrosis
19 17279 1 142400000 148000000 Amplification without LOH NOTCH2NL Myelofibrosis
20 18948 1 148000000 149600000 Amplification without LOH LOC388692 Myelofibrosis
21 18949 1 148000000 149600000 Amplification without LOH NBPF16 Myelofibrosis
22 18952 1 148000000 149600000 Deletion without LOH FCGR1C Myelofibrosis
23 19322 1 149600000 153300000 Amplification without LOH LCE1D Myelofibrosis
24 19323 1 149600000 153300000 Amplification without LOH LCE3C Myelofibrosis
25 19324 1 149600000 153300000 Amplification without LOH POGZ Myelofibrosis
26 19325 1 149600000 153300000 Amplification without LOH THEM5 Myelofibrosis
27 20607 1 153300000 154800000 Amplification without LOH KCNN3 Myelofibrosis
28 20845 1 154800000 157300000 Amplification with LOH MIR555 Myelofibrosis
29 20846 1 154800000 157300000 Deletion without LOH LOC645676 Myelofibrosis
30 21201 1 157300000 158800000 Amplification without LOH OR6N2 Myelofibrosis
31 21202 1 157300000 158800000 Amplification without LOH OR6Y1 Myelofibrosis
32 21203 1 157300000 158800000 Deletion without LOH CD5L Myelofibrosis
33 21465 1 158800000 163800000 Amplification without LOH C1orf110 Myelofibrosis
34 21466 1 158800000 163800000 Amplification without LOH VSIG8 Myelofibrosis
35 21734 1 16100000 20300000 Amplification withou t LOH ARHGEF10L Myelofibrosis
36 21735 1 16100000 20300000 Amplification withou t LOH NBPF1 Myelofibrosis
37 21736 1 16100000 20300000 Amplification withou t LOH PAX7 Myelofibrosis
38 21737 1 16100000 20300000 Amplification withou t LOH RCC2 Myelofibrosis
39 21738 1 16100000 20300000 Amplification withou t LOH UQCRHL Myelofibrosis
40 21740 1 16100000 20300000 Copy-Neutral LOH ATP13A2 Myelofibrosis
41 21743 1 16100000 23800000 Copy-Neutral LOH MRTO4 Myelofibrosis
42 22129 1 165500000 169100000 Amplification without LOH LOC400794 Myelofibrosis
43 22130 1 165500000 169100000 Amplification without LOH MIR921 Myelofibrosis
44 22131 1 165500000 169100000 Deletion without LOH FMO9P Myelofibrosis
45 22825 1 169100000 171200000 Amplification without LOH NME7 Myelofibrosis
46 22829 1 169100000 171200000 Deletion without LOH KIFAP3 Myelofibrosis
47 23058 1 171200000 174300000 Amplification without LOH C1orf105 Myelofibrosis
48 23059 1 171200000 174300000 Deletion without LOH BAT2L2 Myelofibrosis
49 23060 1 171200000 174300000 Deletion without LOH DNM3 Myelofibrosis
50 23061 1 171200000 174300000 Deletion without LOH SLC9A11 Myelofibrosis

Expression for Myelofibrosis

Search GEO for disease gene expression data for Myelofibrosis.

Pathways for Myelofibrosis

Pathways related to Myelofibrosis according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 BMP6 FGF2 FLT3 JAK2 KIT STAT5B
2
Show member pathways
13.4 BMP6 EPO FLT3 IFNA2 JAK2 KIT
3
Show member pathways
13.29 FGF2 FLT3 IFNA2 JAK2 KIT STAT5B
4
Show member pathways
13.28 BMP6 FGF2 FLT3 KIT TGFB1 THPO
5
Show member pathways
13.28 BMP6 FGF2 FLT3 JAK2 KIT STAT5B
6
Show member pathways
13.25 BMP6 FGF2 JAK2 KIT TGFB1 THPO
7
Show member pathways
13.23 CD177 GATA1 IFNA2 JAK2 MPL TGFB1
8
Show member pathways
13.22 BMP6 FGF2 FLT3 KIT TGFB1 THPO
9
Show member pathways
13.02 BMP6 FGF2 KIT TGFB1 THPO TIMP1
10
Show member pathways
12.97 BMP6 EPO FGF2 FLT3 IFNA2 JAK2
11
Show member pathways
12.96 BMP6 FGF2 JAK2 KIT TGFB1 THPO
12
Show member pathways
12.65 BMP6 FGF2 TGFB1 THPO TIMP1
13 12.62 FGF2 FLT3 KIT STAT5B TGFB1
14 12.54 EPO FGF2 IFNA2 JAK2 KIT
15 12.48 GATA1 JAK2 KIT MPL STAT5B
16
Show member pathways
12.31 FLT3 KIT STAT5B TGFB1
17 12.06 FGF2 FLT3 JAK2 KIT
18 12.01 FGF2 GATA1 TGFB1 THPO
19
Show member pathways
12.01 EPO JAK2 KIT STAT5B TGFB1
20 11.92 FGF2 JAK2 TGFB1 TIMP1
21
Show member pathways
11.88 JAK2 STAT5B TGFB1
22
Show member pathways
11.87 EPO IFNA2 JAK2 MPL STAT5B THPO
23
Show member pathways
11.86 JAK2 STAT5B TGFB1
24 11.84 JAK2 STAT5B TGFB1
25
Show member pathways
11.83 EPO JAK2 STAT5B
26 11.81 EPO FLT3 KIT THPO
27 11.78 FGF2 TGFB1 TIMP1
28 11.69 BMP6 FGF2 TGFB1 THPO TIMP1
29 11.68 FLT3 IFNA2 KIT TGFB1
30 11.64 BMP6 FGF2 KIT TGFB1 THPO
31 11.62 FGF2 TGFB1 TIMP1
32 11.61 FGF2 FKBP5 TET2
33 11.58 EPO IFNA2 JAK2 STAT5B
34 11.55 BMP6 FGF2 STAT5B TGFB1
35 11.52 FGF2 KIT TGFB1
36 11.35 EPO FGF2 KIT TGFB1
37 11.23 JAK2 MPL STAT5B THPO
38 11.17 EPO FLT3 IFNA2 KIT MPL THPO
39 10.97 JAK2 STAT5B TIMP1

GO Terms for Myelofibrosis

Cellular components related to Myelofibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 CALR EPO KIT MPL TGFB1
2 extracellular space GO:0005615 9.28 BMP6 CALR EPO FGF2 IFNA2 KIT

Biological processes related to Myelofibrosis according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.98 EPO HMGA2 MPL TGFB1 THPO
2 MAPK cascade GO:0000165 9.96 FGF2 JAK2 KIT TGFB1
3 blood coagulation GO:0007596 9.91 CD177 GATA1 IFNA2 JAK2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 EPO FGF2 TGFB1 THPO
5 regulation of apoptotic process GO:0042981 9.88 BMP6 CALR FLT3 JAK2 TGFB1
6 male gonad development GO:0008584 9.87 GATA1 HMGA2 KIT
7 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 HMGA2 JAK2 KIT
8 response to estradiol GO:0032355 9.85 CALR STAT5B TGFB1
9 response to organic substance GO:0010033 9.84 CALR TGFB1 TIMP1
10 wound healing GO:0042060 9.83 FGF2 TGFB1 TIMP1
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 GATA1 JAK2 TGFB1
12 peptidyl-tyrosine phosphorylation GO:0018108 9.83 FGF2 FLT3 JAK2 KIT STAT5B
13 hemopoiesis GO:0030097 9.81 FLT3 KIT TET2
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 FLT3 JAK2 KIT
15 somatic stem cell population maintenance GO:0035019 9.79 FGF2 HMGA2 KIT
16 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.71 IFNA2 JAK2 KIT
17 positive regulation of MAP kinase activity GO:0043406 9.71 FGF2 FLT3 KIT TGFB1
18 cell activation GO:0001775 9.69 TGFB1 TIMP1
19 hyaluronan catabolic process GO:0030214 9.69 FGF2 TGFB1
20 embryonic hemopoiesis GO:0035162 9.69 GATA1 KIT
21 negative regulation of blood vessel endothelial cell migration GO:0043537 9.68 FGF2 TGFB1
22 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.68 JAK2 STAT5B
23 cellular response to thyroid hormone stimulus GO:0097067 9.68 GATA1 KIT
24 positive regulation of transcription regulatory region DNA binding GO:2000679 9.67 HMGA2 TGFB1
25 negative regulation of cell-cell adhesion GO:0022408 9.67 JAK2 TGFB1
26 myeloid cell differentiation GO:0030099 9.67 GATA1 TET2 THPO
27 erythrocyte differentiation GO:0030218 9.67 EPO GATA1 JAK2 KIT
28 dendritic cell differentiation GO:0097028 9.65 FLT3 GATA1
29 positive regulation of SMAD protein import into nucleus GO:0060391 9.64 BMP6 TGFB1
30 positive regulation of phospholipase C activity GO:0010863 9.63 FGF2 KIT
31 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.63 EPO JAK2 KIT
32 cytokine-mediated signaling pathway GO:0019221 9.63 FLT3 IFNA2 JAK2 KIT MPL STAT5B
33 germ cell migration GO:0008354 9.62 KIT TGFB1
34 negative regulation of trophoblast cell migration GO:1901164 9.58 CALR TIMP1
35 negative regulation of intracellular steroid hormone receptor signaling pathway GO:0033144 9.56 CALR HMGA2
36 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.56 FGF2 FLT3 KIT TGFB1
37 erythropoietin-mediated signaling pathway GO:0038162 9.52 EPO KIT
38 thrombopoietin-mediated signaling pathway GO:0038163 9.51 MPL THPO
39 myeloid progenitor cell differentiation GO:0002318 9.5 FLT3 KIT TET2
40 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.35 EPO FLT3 IFNA2 JAK2 KIT
41 positive regulation of cell proliferation GO:0008284 9.32 CALR EPO FGF2 FLT3 HMGA2 JAK2
42 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.11 BMP6 FGF2 GATA1 HMGA2 STAT5B TET2
43 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.08 BMP6 CALR EPO GATA1 HMGA2 TGFB1
44 negative regulation of apoptotic process GO:0043066 10.04 EPO GATA1 HMGA2 STAT5B TIMP1
45 positive regulation of transcription, DNA-templated GO:0045893 10.02 EPO FGF2 GATA1 HMGA2 IFNA2 TGFB1

Molecular functions related to Myelofibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.55 FGF2 FLT3 JAK2 KIT STAT5B
2 DNA binding, bending GO:0008301 9.4 GATA1 HMGA2
3 C2H2 zinc finger domain binding GO:0070742 9.37 GATA1 HMGA2
4 growth factor activity GO:0008083 9.35 BMP6 FGF2 TGFB1 THPO TIMP1
5 glucocorticoid receptor binding GO:0035259 9.32 FLT3 STAT5B
6 cytokine activity GO:0005125 9.1 BMP6 FGF2 IFNA2 TGFB1 THPO TIMP1
7 protein binding GO:0005515 10.16 CALR CD177 EPO FGF2 FKBP5 FLT3

Sources for Myelofibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....